company background image

Swedencare OM:SECARE Stock Report

Last Price


Market Cap







26 Jun, 2022


Company Financials +
SECARE fundamental analysis
Snowflake Score
Future Growth5/6
Past Performance4/6
Financial Health4/6

SECARE Stock Overview

Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products.

Swedencare Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Swedencare
Historical stock prices
Current Share Pricekr86.92
52 Week Highkr159.00
52 Week Lowkr67.56
1 Month Change-6.11%
3 Month Change-22.32%
1 Year Change-10.94%
3 Year Change452.93%
5 Year Change1,624.60%
Change since IPO2,314.44%

Recent News & Updates

Shareholder Returns

SECARESE PharmaceuticalsSE Market

Return vs Industry: SECARE exceeded the Swedish Pharmaceuticals industry which returned -15.4% over the past year.

Return vs Market: SECARE exceeded the Swedish Market which returned -23.6% over the past year.

Price Volatility

Is SECARE's price volatile compared to industry and market?
SECARE volatility
SECARE Average Weekly Movement9.4%
Pharmaceuticals Industry Average Movement9.1%
Market Average Movement7.4%
10% most volatile stocks in SE Market12.2%
10% least volatile stocks in SE Market4.7%

Stable Share Price: SECARE is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: SECARE's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

1993517Hakan Lagerberg

Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the formation of plaque and tartar; ProDen PlaqueOff dental bites, a pet dental product; ProDen PlaqueOff powder cat; ProDen PlaqueOff dental bones for dogs; ProDen PlaqueOff mini dental care bones, a chewy bone for smaller dogs; and ProDen PlaqueOff soft chews for dogs and cats. The company also provides dietary supplements for cats, dogs, and horses under the NutriScience brand, such as Glucosamine and Stomax used to renew joint cartilage, bones, muscles, ligaments, and sinews; ArthriAid for joints and mobility; KalmAid, which helps to calm nervous dogs; and OmegaAid and RevitalAid, a feed supplement used for healthy skin and coat.

Swedencare Fundamentals Summary

How do Swedencare's earnings and revenue compare to its market cap?
SECARE fundamental statistics
Market Capkr13.74b
Earnings (TTM)kr57.23m
Revenue (TTM)kr1.02b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SECARE income statement (TTM)
Cost of Revenuekr507.23m
Gross Profitkr512.04m
Other Expenseskr454.81m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Jul 28, 2022

Earnings per share (EPS)0.36
Gross Margin50.24%
Net Profit Margin5.61%
Debt/Equity Ratio21.1%

How did SECARE perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio
We’ve recently updated our valuation analysis.


Is SECARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SECARE?

Other financial metrics that can be useful for relative valuation.

SECARE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue14.8x
Enterprise Value/EBITDA100x
PEG Ratio6.5x

Price to Sales Ratio vs Peers

How does SECARE's PS Ratio compare to its peers?

SECARE PS Ratio vs Peers
The above table shows the PS ratio for SECARE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average11.8x
CAMX Camurus
KARO Karo Pharma
CALTX Calliditas Therapeutics
IRLAB A IRLAB Therapeutics
SECARE Swedencare

Price-To-Sales vs Peers: SECARE is expensive based on its Price-To-Sales Ratio (13.5x) compared to the peer average (11.8x).

Price to Earnings Ratio vs Industry

How does SECARE's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?

Price-To-Sales vs Industry: SECARE is good value based on its Price-To-Sales Ratio (13.5x) compared to the Swedish Pharmaceuticals industry average (15.2x)

Price to Sales Ratio vs Fair Ratio

What is SECARE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SECARE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13.5x
Fair PS Ratio12.6x

Price-To-Sales vs Fair Ratio: SECARE is expensive based on its Price-To-Sales Ratio (13.5x) compared to the estimated Fair Price-To-Sales Ratio (12.6x).

Share Price vs Fair Value

What is the Fair Price of SECARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SECARE (SEK86.92) is trading below our estimate of fair value (SEK185.31)

Significantly Below Fair Value: SECARE is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: SECARE is poor value based on its PEG Ratio (6.5x)

Discover undervalued companies

Future Growth

How is Swedencare forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score


Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SECARE's forecast earnings growth (36.9% per year) is above the savings rate (0.3%).

Earnings vs Market: SECARE's earnings (36.9% per year) are forecast to grow faster than the Swedish market (9.8% per year).

High Growth Earnings: SECARE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SECARE's revenue (21.5% per year) is forecast to grow faster than the Swedish market (5.6% per year).

High Growth Revenue: SECARE's revenue (21.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SECARE's Return on Equity is forecast to be low in 3 years time (5.7%).

Discover growth companies

Past Performance

How has Swedencare performed over the past 5 years?

Past Performance Score


Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SECARE has high quality earnings.

Growing Profit Margin: SECARE's current net profit margins (5.6%) are lower than last year (10.1%).

Past Earnings Growth Analysis

Earnings Trend: SECARE's earnings have grown significantly by 31.5% per year over the past 5 years.

Accelerating Growth: SECARE's earnings growth over the past year (69.1%) exceeds its 5-year average (31.5% per year).

Earnings vs Industry: SECARE earnings growth over the past year (69.1%) exceeded the Pharmaceuticals industry 17.9%.

Return on Equity

High ROE: SECARE's Return on Equity (0.9%) is considered low.

Discover strong past performing companies

Financial Health

How is Swedencare's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: SECARE's short term assets (SEK945.7M) exceed its short term liabilities (SEK495.3M).

Long Term Liabilities: SECARE's short term assets (SEK945.7M) do not cover its long term liabilities (SEK2.3B).

Debt to Equity History and Analysis

Debt Level: SECARE's net debt to equity ratio (16.8%) is considered satisfactory.

Reducing Debt: SECARE's debt to equity ratio has reduced from 38.3% to 21.1% over the past 5 years.

Debt Coverage: SECARE's debt is not well covered by operating cash flow (11.7%).

Interest Coverage: SECARE's interest payments on its debt are well covered by EBIT (5.8x coverage).

Balance Sheet

Discover healthy companies


What is Swedencare current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: SECARE's dividend (0.23%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.67%).

High Dividend: SECARE's dividend (0.23%) is low compared to the top 25% of dividend payers in the Swedish market (5.41%).

Stability and Growth of Payments

Stable Dividend: SECARE is not paying a notable dividend for the Swedish market, therefore no need to check if payments are stable.

Growing Dividend: SECARE is not paying a notable dividend for the Swedish market, therefore no need to check if payments are increasing.

Earnings Payout to Shareholders

Earnings Coverage: SECARE is not paying a notable dividend for the Swedish market.

Cash Payout to Shareholders

Cash Flow Coverage: SECARE is not paying a notable dividend for the Swedish market.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Hakan Lagerberg (53 yo)





Mr. Hakan Lagerberg serves as an Independent Director at Polygiene Group AB (formerly known as Polygiene AB (publ.)) since May 17, 2019. He serves as Chief Executive Officer at Swedencare AB (publ) since J...

CEO Compensation Analysis

Compensation vs Market: Hakan's total compensation ($USD209.75K) is below average for companies of similar size in the Swedish market ($USD972.85K).

Compensation vs Earnings: Insufficient data to compare Hakan's compensation with company performance.

Leadership Team

Experienced Management: SECARE's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Experienced Board: SECARE's board of directors are considered experienced (4.9 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: SECARE insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 50%.

Top Shareholders

Company Information

Swedencare AB (publ)'s employee growth, exchange listings and data sources

Key Information

  • Name: Swedencare AB (publ)
  • Ticker: SECARE
  • Exchange: OM
  • Founded: 1993
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr13.743b
  • Shares outstanding: 158.11m
  • Website:

Number of Employees


  • Swedencare AB (publ)
  • Medeon Science Park
  • Malmö
  • Skåne County
  • 205 12
  • Sweden


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/23 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.